GlaxoSmithKline remains top of the league table, but its lead is shrinking, with two newcomers moving into the top three closely behind and more companies joining the ranks of the leaders. The industry as a whole is gradually progressing.
GlaxoSmithKline remains at the top of the Index, with a marginal improvement in performance since 2010, and this year, Johnson & Johnson and Sanofi follow closely in 2nd and 3rd positions. Seventeen out of the 20 companies are doing more than they were at the time of the 2010 Index to bring medicine to those who need it the most. At the top end, membership of the leading group has expanded from three companies in 2010 to seven, and there is a smaller difference between their scores than there was in 2010. Meanwhile, the gap has also narrowed between the bottom few companies and the top performers. This is notable given the fact that the Index set the bar higher this year in many areas. The position of Gilead, in 5th place, and Novo Nordisk, in 6th place, in the leading group illustrates that companies don’t necessarily need to have scale
to perform well in access to medicine. The leading group are also the most transparent about their access activities, which contributes to higher scores because the initiatives are more visible, and therefore amenable to scoring.